angieb
![]()
Posts:12
Has anyone heard anything about this drug? It is apparently for NSCLC EGFR position patients. The trial will include patients with and without T790 mutation. We are exploring options. Progression on Tarceva and chemo was not at all effective. Clovis 1686 will open soon in our area. We were told the response rate for non T790 is around 30% (is that good or bad). My husband's tumor is poorly defined adenosquamous, so we've been told Opdivo may also be an option (not sure of expected response rate for poorly defined EGFR positive adenosquamous. And now this new trial that I just read about. Any thoughts?? Thanks
Forums
Reply # - March 23, 2015, 12:22 AM
Hi Angie,
Hi Angie,
We don't have any info written on it yet probably since the clinical trials haven't yet begun. Perhaps someone who is planning to enroll will chime in.
You may have already seen this. NCI has this to say,
"EGFR T790M inhibitor PF-06747775
An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. EGFR T790M inhibitor PF-06747775 specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06747775 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which can inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Check for active clinical trials or closed clinical trials using this agent. " http://www.cancer.gov/drugdictionary?cdrid=768709
Reply # - March 23, 2015, 02:53 PM
Hi Angie,
Hi Angie,
I haven't seen discussion of this new agent here, and not much elsewhere other than trial listings. I don't that think it would be possible to state an expected response rate for a subcategory such as EGFR positive adenosquamous. It's a relatively small category and it's also not a well-defined group, since there can be great variation from patient to patient in terms of how much of the cancer is adenocarcinoma and how much is squamous.
For previously treated lung cancer, a 30% response rate is good, since a response is defined as a specific percentage of tumor shrinkage, usually 50%. Since a good response to second and later line therapy is often more in the nature of stable disease or minor shrinkage than such dramatic tumor response, the percentage of patients who benefit from the therapy would certainly be much higher than 30%.
JimC
Forum moderator